May 21st, 2018 – Vancouver, British Columbia – Tabu Equity Investments Inc. (the “Company” or “Tabu”) announces TABU has signed a preliminary agreement with a foreign Investment group with holdings in over 30 industrial and technological companies world wide. The firm is offering to provide Tabu Equity Investments with a $10,000,000 financing. The proposed financing allows investors to purchase Tabu shares at a price of $.50 cents per share, along with one half warrant at $.75 cents. Due diligence is expected to take 30 days and during this period Tabu will work toward a final agreement. Tabu intends to use these funds to expand its product line and initiate its business plan. Tabu expects to begin production of at least 20 SKU’s (products) by October 2018 with deliveries to commence by November 2018. Tabu has identified over 60 SKU’s that will be sold into the market through its distribution system, by the 2nd quarter of 2019. This financing will allow the company to not only fund this production, but to also begin making acquisitions on the retail dispensary side. Tabu is aggressively rolling out its business plan as described on the company’s website, with acquisitions in production, media and distribution expected to continue.

RWE Completes Valuation of Tabu Equity Investments.
RWE has completed its valuation of Tabu, the results of which will be announced shortly. The valuation is in-line with the companies expectations and takes into consideration Tabu’s excellent progress in the areas of product and brand development as well as distribution. Tabu President Lisa Palleson stated: “Having a third party firm with the credentials of RWE, confirms our long standing belief that Tabu has evolved into a truly important brand.” Forward-looking statements may include, without limitation, statements including statements related to Tabu’s transactions and business related to cannabis and future news releases. Although Tabu has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change.